logo
Frontline workers feel so disconnected, nearly half don't know who their CEO is

Frontline workers feel so disconnected, nearly half don't know who their CEO is

Fast Company4 hours ago

Frontline workers, those non-desk workers who do some of the most demanding jobs, don't always feel connected to the company they work for. In fact, many say their team has an entirely distinct culture of its own and that communication with their company leaves a lot to be desired.
According to a new global survey of 7,550 workers from Workvivo by Zoom, while frontline workers make up 80% of the global workforce, many say they don't get the recognition they deserve. Frontline workers know how essential their duties are. In fact, 49% say they feel their impact is greater than that of their office colleagues. They just don't feel recognized for it. Likewise, 40% say their company doesn't care about them as a person.
A separate corporate culture
Overall, according to the new findings, frontline workers feel largely disconnected to in-office culture. A staggering 87% said that their company's culture doesn't apply to frontline workers. Half of frontline workers feel that their team has its own specific culture that doesn't mirror that of the company's overall vibe. And a huge chunk of frontline workers feel so disconnected from their company they don't even know who runs it. Nearly half (46%) said they don't know who their CEO is.
One glaring reason why frontline workers feel so disconnected from in-office culture seems to be a lack of communication. According to the report, 38% say they have feedback for higher-ups, but no way of communicating it. Forty-two percent say that the leaders at their company aren't good at reaching out to their team. Forty-eight percent say their company's communication feels irrelevant to frontline workers.
Connecting with frontline staff
Another recent report by Staffbase similarly found a communication disconnect among frontline workers. The research found only 9% of non-desk workers were very satisfied with internal communication. And it seems to be an issue that leads to overall workplace unhappiness and drives turnover. Sixty-three percent of employees who are considering leaving their position say poor internal communication is a factor.
Meanwhile, most frontline workers aren't checked out. In fact, they want more communication. The latest report found that 69% of frontline workers want to better understand their company's decisions. Essentially, those on the frontlines want clear communication, to feel connected, and to be heard by the company they represent.
'Our research shows that frontline employees feel disconnected not because they care less, but because they are engaged less,' said Gideon Pridor, CMO & chief storyteller at Workvivo, by Zoom in a press release. 'To close this critical gap, organizations need to recognize frontline contributions in real time, communicate in ways that are relevant and accessible, and provide clear and visible paths for growth.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

Yahoo

timean hour ago

  • Yahoo

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

Featuring Serina Therapeutics' CEO - Wednesday, June 11, 2025 Entering year 5 of a biotech bear market, approximately 25% of the 700 – 800 publicly traded US biotech companies have negative enterprise values Recognize the patterns that can lead to strong investment returns Meet with Serina's CEO Steven A. Ledger Register at HUNTSVILLE, AL, June 09, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ('Serina') (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is pleased to announce that Serina's CEO, Steven A. Ledger will present at Tribe Public's Webinar Presentation and Q&A Event titled "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" The Event is scheduled to begin at 8:30 am pacific / 11:30 am eastern on Wednesday, June 11, 2025. To register to join the complimentary event, please visit the Tribe Public LLC at Once registered, participants may begin forwarding their questions for the CEO to Tribe Public at research@ or share their questions via the ZOOM chat feature during the event. Tribe Public's Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management. About Serina Therapeutics Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina's POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit About Tribe Public LLC Tribe Public LLC, headquartered in San Francisco, California, is a distinguished organization that facilitates corporate sponsored global webinars and in-person meetings events across 36 premier venues throughout the United States. Tribe Public's events are tailored to address topics of significant interest to its members, with a particular emphasis on providing direct access to management teams and leading experts from diverse sectors who seek to enhance awareness of their products, achievements, and strategic initiatives. The Tribe's membership is composed primarily of Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and media professionals, all of whom benefit from exclusive opportunities for business development, community building, and informed dialogue in a collegial setting. Members are actively encouraged to shape the event agenda by submitting speaker and company preferences through Tribe Public's complimentary 'Wish List' process on its website, ensuring that the programming reflects the evolving interests of its sophisticated community. To learn more about Tribe Public's offerings and to participate in upcoming events, visit their website at: Cautionary Statement Regarding Forward-Looking Statement This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management's current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina's POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in Serina's Annual Report on Form 10-K, and Serina's other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. For inquiries, please contact:Stefan Riley sriley@ (256) 327-9630Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store